1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        North America Metastatic Cancer Drugs Market – By Cancer Type

1.3.2        North America Metastatic Cancer Drugs Market – By Route of Administration

1.3.3        North America Metastatic Cancer Drugs Market – By Drug Class

1.3.4        North America Metastatic Cancer Drugs Market – By Product

1.3.5        North America Metastatic Cancer Drugs Market – By End User

1.3.6        North America Metastatic Cancer Drugs Market – By Country

2.           North America Metastatic Cancer Drugs Market – Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           North America Metastatic Cancer Drugs Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        North America– PEST Analysis

4.3         Expert Opinion

5.           North America Metastatic Cancer Drugs Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        High Prevalence of Metastatic Cancer

5.1.2        Government Initiatives to Support Developments in Cancer Treatment

5.2         Market Restraints

5.2.1        High Cost of Oncology Drugs

5.3         Market Opportunities

5.3.1        Investments in Artificial Intelligence for Oncology Drug Development

5.4         Future Trends

5.4.1        Increase in Launch of Metastatic Cancer Drugs

5.5         Impact analysis

6.           North America Metastatic Cancer Drugs Market – Country Analysis

6.1         North America Metastatic Cancer Drugs Market Revenue Forecast and Analysis

7.           North America Metastatic Cancer Drug Market Analysis – By Cancer Type

7.1         Overview

7.2         North America Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)

7.2.1        North America: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

7.3         Breast Cancer

7.3.1        Overview

7.3.2        Breast Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.4         Lung Cancer

7.4.1        Overview

7.4.2        Lung Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.5         Liver Cancer

7.5.1        Overview

7.5.2        Liver Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.6         Hematological Cancer

7.6.1        Overview

7.6.2        Hematological Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.7         Brain Cancer

7.7.1        Overview

7.7.2        Brain Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.8         Prostate Cancer

7.8.1        Overview

7.8.2        Prostate Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.9         Pancreatic Cancer

7.9.1        Overview

7.9.2        Pancreatic Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.10      Others

7.10.1     Overview

7.10.2     Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.           North America Metastatic Cancer Drug Market – By Route of Administration

8.1         Overview

8.2         North America Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)

8.2.1        North America: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

8.3         Intravenous

8.3.1        Overview

8.3.2        Intravenous: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.4         Intramuscular

8.4.1        Overview

8.4.2        Intramuscular: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.5         Oral

8.5.1        Overview

8.5.2        Oral: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.6         Others

8.6.1        Overview

8.6.2        Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.           North America Metastatic Cancer Drug Market – By Drug Class

9.1         Overview

9.2         North America Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)

9.2.1        North America: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

9.3         HER2 Inhibitors

9.3.1        Overview

9.3.2        HER2 Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.4         Immune Checkpoints Inhibitors

9.4.1        Overview

9.4.2        Immune Checkpoints Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.5         PARP Inhibitors

9.5.1        Overview

9.5.2        PARP Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.6         Kinase Inhibitors

9.6.1        Overview

9.6.2        Kinase Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.7         Others

9.7.1        Overview

9.7.2        Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10.        North America Metastatic Cancer Drug Market – By Product

10.1      Overview

10.2      North America Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)

10.2.1     North America: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

10.3      Branded

10.3.1     Overview

10.3.2     Branded: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10.4      Generics and Biosimilars

10.4.1     Overview

10.4.2     Generics and Biosimilars: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.        North America Metastatic Cancer Drug Market – By End User

11.1      Overview

11.2      North America Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)

11.2.1     North America: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

11.3      Hospital

11.3.1     Overview

11.3.2     Hospitals: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.4      Specialty Clinic

11.4.1     Overview

11.4.2     Specialty Clinics: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.5      Others

11.5.1     Overview

11.5.2     Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

12.        North America Metastatic Cancer Drugs Market – Regional Analysis

12.1      North America Metastatic Cancer Drugs Market Revenue Forecast and Analysis

12.1.1     North America Metastatic Cancer Drugs Market Revenue Forecast and Analysis

12.1.1.1       US: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.1       US: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.2       US: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.3       US: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.4       US: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.5       US: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.6       US: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

12.1.1.2       Canada: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.1       Canada: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.2       Canada: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.3       Canada: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.4       Canada: North America Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

12.1.1.2.5       Canada: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.6       Canada: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

12.1.1.3       Mexico: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.1       Mexico: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.2       Mexico: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.3       Mexico: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.4       Mexico: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.5       Mexico: North America Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

12.1.1.3.6       Mexico: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

13.        North America Metastatic Cancer Drug Market –Industry Landscape

13.1      Overview

13.2      Growth Strategies in the North America Metastatic Cancer Drug Market, 2021-2028

13.3      Inorganic Developments

13.3.1     Overview

13.4      Organic Growth Strategies

13.4.1     Overview

14.        Company Profiles

14.1      AbbVie Inc.

14.1.1     Key Facts

14.1.2     Business Description

14.1.3     Products and Services

14.1.4     Financial Overview

14.1.5     SWOT Analysis

14.1.6     Key Developments

14.2      Amgen Inc.

14.2.1     Key Facts

14.2.2     Business Description

14.2.3     Products and Services

14.2.4     Financial Overview

14.2.5     SWOT Analysis

14.2.6     Key Developments

14.3      Bristol-Myers Squibb Company

14.3.1     Key Facts

14.3.2     Business Description

14.3.3     Products and Services

14.3.4     Financial Overview

14.3.5     SWOT Analysis

14.3.6     Key Developments

14.4      F. HOFFMANN-LA ROCHE LTD.

14.4.1     Key Facts

14.4.2     Business Description

14.4.3     Products and Services

14.4.4     Financial Overview

14.4.5     SWOT Analysis

14.4.6     Key Developments

14.5      Novartis AG

14.5.1     Key Facts

14.5.2     Business Description

14.5.3     Products and Services

14.5.4     Financial Overview

14.5.5     SWOT Analysis

14.5.6     Key Developments

14.6      Astrazeneca

14.6.1     Key Facts

14.6.2     Business Description

14.6.3     Products and Services

14.6.4     Financial Overview

14.6.5     SWOT Analysis

14.6.6     Key Developments

14.7      Eli Lilly and Company.

14.7.1     Key Facts

14.7.2     Business Description

14.7.3     Products and Services

14.7.4     Financial Overview

14.7.5     SWOT Analysis

14.7.6     Key Developments

14.8      MERCK KGaA

14.8.1     Key Facts

14.8.2     Business Description

14.8.3     Products and Services

14.8.4     Financial Overview

14.8.5     SWOT Analysis

14.8.6     Key Developments

14.9      Pfizer Inc. (Arena Pharmaceutical GmbH)

14.9.1     Key Facts

14.9.2     Business Description

14.9.3     Products and Services

14.9.4     Financial Overview

14.9.5     SWOT Analysis

14.9.6     Key Developments

14.10   Johnson and Johnson Services, Inc.

14.10.1  Key Facts

14.10.2  Business Description

14.10.3  Products and Services

14.10.4  Financial Overview

14.10.5  SWOT Analysis

14.10.6  Key Developments

15.        Appendix

15.1      About The Insight Partners

15.2      Glossary of Terms

LIST OF TABLES

Table 1.             North America: North America Metastatic Cancer Drug Market, – Revenue and Forecast to 2028 (USD Million)

Table 2.             North America: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 3.             North America: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 4.             North America: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 5.             North America: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 6.             North America: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 7.             US: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 8.             US: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 9.             US: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 10.          US: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 11.          US: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 12.          Canada: North America Metastatic Cancer Drug Market, by Cancer Type - Revenue and Forecast to 2028 (USD Million)

Table 13.          Canada: North America Metastatic Cancer Drug Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)

Table 14.          Canada: North America Metastatic Cancer Drug Market, by Drug Class - Revenue and Forecast to 2028 (USD Million)

Table 15.          Canada: North America Metastatic Cancer Drug Market, by Product - Revenue and Forecast to 2028 (USD Million)

Table 16.          Canada: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 17.          Mexico: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 18.          Mexico: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 19.          Mexico: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 20.          Mexico: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 21.          Mexico: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 22.          Recent Inorganic Growth Strategies in the North America Metastatic Cancer Drug Market

Table 23.          Recent Organic Growth Strategies in the North America Metastatic Cancer Drug Market

Table 24.          Glossary of Terms, North America Metastatic Cancer Drugs Market

LIST OF FIGURES

Figure 1.           North America Metastatic Cancer Drugs Market Segmentation

Figure 2.           North America Metastatic Cancer Drugs Market Overview

Figure 3.           The PARP Inhibitors Segment Held The Largest Share of Drug Class Segment in North America Metastatic Cancer Drugs Market

Figure 4.           US Is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.           North America PEST Analysis

Figure 6.           Expert Opinion

Figure 7.           North America Metastatic Cancer Drugs Market Impact Analysis of Driver and Restraints

Figure 8.           North America Metastatic Cancer Drugs Market – Revenue Forecast and Analysis – 2021- 2028

Figure 9.           North America Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)

Figure 10.        Breast Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 11.        Lung Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12.        Liver Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        Hematological Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        Brain Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15.        Prostate Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        Pancreatic Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        North America Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)

Figure 19.        Intravenous: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20.        Intramuscular: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        Oral: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        North America Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)

Figure 24.        HER2 Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        Immune Checkpoints Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.        PARP Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.        Kinase Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28.        Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        North America Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)

Figure 30.        Branded: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31.        Generics and Biosimilars: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.        North America Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)

Figure 33.        Hospitals: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34.        Specialty Clinics: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35.        Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36.        North America Metastatic Cancer Drugs Market – By Country Forecast and Analysis – 2021- 2028.

Figure 37.        North America: North America Metastatic Cancer Drug Market, by Key Country – Revenue (2021) (USD Million)

Figure 38.        US: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 39.        Canada: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 40.        Mexico: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 41.        Growth Strategies in the North America Metastatic Cancer Drug Market, 2021-2028